Immunogenicity and Safety of Multiple Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adult and Elderly Subjects.
Phase of Trial: Phase II
Latest Information Update: 19 Jun 2013
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary)
- Indications Influenza A virus H1N1 subtype
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi
- 16 Dec 2009 Immunogenicity results were published in the Lancet.
- 11 Nov 2009 Status changed from active, no longer recruiting to completed, based on information from a Sanofi Pasteur media release.
- 11 Nov 2009 Final results have been announced by Sanofi Pasteur in a media release.